| HOME >> MEDICINE >> TECHNOLOGY |
(2,964)(3,403)Amortization of premium on investment securities, net
1,640458Deferred taxes
-(29)Realized gain on sale of investment securities
(6)-Loss on sale of property and equipment
36Changes in operating assets and liabilities:Accounts receivable
(12,057)(10,165)Other current and long-term assets
(53)(713)Accounts payable and accrued expenses
(138)2,922Accrued compensation
3,0664,552Income taxes
1,2293,756Deferred revenues
229754Deferred rent
13743Net cash provided by operating activities
23,13333,588Investing activities:Purchase of property and equipment
(26,332)(3,240)Purchase of investment securities
(102,890)(120,508)Proceeds from sales and maturities of investment securities
95,82067,434Purchase of intangibles
(1,520)(150)Release of restricted cash
9090Net cash used in investing activities
(34,832)(56,374)Financing activities:Proceeds from issuance of common stock, net
1,4961,609Payment of taxes for issuance of restricted stock units
(595)(458)Excess tax benefits from stock-based compensation awards
2,9643,403Repurchase of common stock
(43)(11)Net cash provided by financing activities
3,8224,543Net decrease in cash and cash equivalents
(7,877)(18,243)Cash and cash equivalents at beginning of period
27,94538,108Cash and cash equivalents at end of period$
20,068$
9,865
'/>"/>
| SOURCE Genoptix, Inc. Copyright©2010 PR Newswire. All rights reserved |